By Fineline Cube 
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the initiation of a Phase III clinical study for its Fumaining (luvometinib), an MEK 1/2 inhibitor, in pediatric low-grade glioma in mainland China. This marks a significant advancement in the development of targeted therapies for pediatric cancers.
Fumaining’s Approved Indications
The in-house developed innovative small molecule chemical drug has already been approved in China for the treatment of adult Langerhans cell histiocytosis (LCH) and pediatric and adolescent patients (aged 2 and above) with inoperable plexiform neurofibromas (PN). The drug has demonstrated efficacy and safety in these patient populations, providing new treatment options where limited alternatives previously existed.
Ongoing Clinical Development
In addition to this newly initiated trial, Fumaining is also undergoing Phase II/III clinical studies for multiple other indications in China. These include adult neurofibromatosis type 1 (NF1) and pediatric LCH. Some of these studies have been awarded Breakthrough Therapy Designations in the country, highlighting the potential of Fumaining to address significant unmet medical needs.-Fineline Info & Tech